ArticleHead and neck pathology2026
Calcified Chondroid Mesenchymal Neoplasm of the Temporomandibular Joint Region: Three Cases Illustrating Recent Developments and Diagnostic Pitfalls.
Article in Head and neck pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCalcified chondroid mesenchymal neoplasm (CCMN) is a recently described and evolving entity that predominantly arises in the distal extremities andtemporomandibular joint (TMJ) region. CCMN is characterized by FN1 and PDGFRA gene fusions. In the TMJ region, most cases previously described as tophaceous pseudogout (i.e., mass-forming calcium pyrophosphate deposition disease) are now being increasingly recognized as CCMN. There is considerable morphologic overlap between CCMN and tophaceous pseudogout (TPG), and the detection of FN1 and PDGFRA gene rearrangements is critical in distinguishing CCMN from TPG. We aim to identify, from our archival records, cases of CCMN that were previously diagnosed as TPG.
methodsWe retrospectively reviewed clinical history and histopathology slides of three cases of TMJ region masses initially diagnosed as TPG, and submitted all three cases for targeted RNA sequencing.
resultsCase 1 harbored a canonical FN1::FGFR2 fusion. Case 2 failed targeted RNA sequencing. Case 3 harbored a canonical PDGFRA::USP8 fusion. None of the three cases had clinical history of pseudogout. All three cases were subsequently reclassified as CCMN on review.
conclusionCCMN should be considered as a differential diagnosis in first presentations of 'tophaceous pseudogout' associated with chondroid metaplasia, with targeted molecular testing done as part of the diagnostic process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.